These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33994379)

  • 1. Changing Spectrum of Mineral Bone Disorder in Chronic kidney disease stage 3 to 5 D and Its Associated Factors, A Prospective Cross-Sectional Study from Tertiary Care Hospital in Northern India.
    Sethi S; Sethi N; Sandhu JS; Makkar V; Kaur S; Sohal PM; Mehta S
    Iran J Kidney Dis; 2021 May; 15(3):199-205. PubMed ID: 33994379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of chronic kidney disease-mineral bone disorders in newly detected advanced renal failure patients: A Hospital-based cross-sectional study.
    Etta PK; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2017; 28(4):874-885. PubMed ID: 28748891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
    Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
    Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in kano, northwest nigeria.
    Abdu A; Abdu A; Arogundade FA
    Ann Afr Med; 2019; 18(4):191-195. PubMed ID: 31823953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
    Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
    Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To what extent can we achieve mineral bone metabolism treatment targets suggested by the KDIGO guidelines among chronic kidney disease stage 3 - 5 non-dialysis patients?
    Dincer MT; Ozcan SG; Alagoz S; Karaca C; Gulcicek SH; Trabulus S; Pekpak M; Seyahi N
    Clin Nephrol; 2022 Nov; 98(5):239-246. PubMed ID: 35979902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
    Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population.
    Ngai M; Lin V; Wong HC; Vathsala A; How P
    Clin Nephrol; 2014 Oct; 82(4):231-9. PubMed ID: 25161115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D levels and other biochemical parameters of mineral bone disorders and their association with diastolic dysfunction and left ventricular mass in young nondiabetic adult patients with chronic kidney disease.
    Sonkar SK; Bhutani M; Sonkar GK; Pandey SK; Chandra S; Bhosale V
    Saudi J Kidney Dis Transpl; 2017; 28(4):758-763. PubMed ID: 28748877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineral and bone disorder in hemodialysis patients in the Tibetan Plateau: a multicenter cross-sectional study.
    Dang ZH; Tang C; Li GL; Luobu C; Qing D; Ma ZH; Qu JF; Suolang L; Liu LJ
    Ren Fail; 2019 Nov; 41(1):636-643. PubMed ID: 31269846
    [No Abstract]   [Full Text] [Related]  

  • 16. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study.
    Ghosh B; Brojen T; Banerjee S; Singh N; Singh S; Sharma OP; Prakash J
    Indian J Nephrol; 2012 Jul; 22(4):285-91. PubMed ID: 23162273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
    Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
    Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypes of Mineral Bone Disorder in Chronic Kidney Disease in a Dialysis Population.
    Rojas-Campos E; Ruvalcaba-Contreras N; Campos-Mariz A; Aguilar-Campos A; Andrade-Sierra J; Cerrillos-Gutiérrez JI; Medina-Pérez M; Evangelista-Carrillo L; Banda A; Cueto-Manzano AM
    Arch Med Res; 2024 Jun; 55(4):103008. PubMed ID: 38824883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.